Form D · Biotechnology
SELLAS Life Sciences Group, Inc.
New York, NY · CIK 0001390478
Offering snapshot reported Mar 29, 2024 · SEC filing
- Reported sold
- $18.4M Offering amount: $18.4M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 29, 2024 | Initial | $18,371,336 | No comparison | 4 | SEC filing |
| Aug 31, 2020 | Initial | $9,151,500 | No comparison | 11 | SEC filing |
| Jul 26, 2016 | Initial | $9,100,000 | No comparison | 3 | SEC filing |
| May 24, 2016 | Initial | $24,000,000 | No comparison | 1 | SEC filing |
| Jan 22, 2014 | Initial | $0 | No comparison | 4 | SEC filing |
| Jul 11, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 7, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.4M
- Finders' fees
- $60K
- Form D file number
- 021-509138
Represents the aggregate exercise price of warrants for 13,029,316 shares of common stock issued in connection with a registered direct offering of 11,000,000 shares of common stock and 2,029,316 pre-funded warrants.
$1,399,985.80 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $60,000 is for the reimbursement of expenses incurred by the placement agent.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| A.G.P./Alliance Global Partners | 8361 |
Source: Form D, filed Mar 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark J. Ahn, Ph.D. | Director, Executive |
| William L. Ashton | Director |
| John T. Burns | Executive |
| Richard Chin | Director |
| Richard Chin, M.D. | Director |
| Ryan Dunlap | Executive |
| Irving M. Einhorn | Director |
| Stephen Galliker | Director |
| Mary Ann Gray | Director |
| Mary Ann Gray, Ph.D. | Director |
| Brian Hamilton, M.D., Ph.D. | Executive |
| Sanford J. Hillsberg | Director |
| Katherine Bach Kalin | Director |
| Thomas J. Knapp | Executive |
| Steven A. Kriegsman | Director |
| Bijan Nejadnik | Executive |
| Bijan Nejadnik, M.D. | Executive |
| Rudolph Nisi | Director |
| Rudolph Nisi, M.D. | Director |
| Robert Van Nostrand | Director |
| David A. Scheinberg | Director |
| Mark W. Schwartz | Director, Executive |
| Mark W. Schwartz, Ph.D. | Director |
| Angelos M. Stergiou | Director, Executive |
| Robert L. Van Nostrand | Director |
| John Varian | Director |
| Jane Wasman | Director |
| Barbara A. Wood | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7 Times Square Suite 2503
New York, NY, 10036
New York, NY, 10036